Iron chelation, angiogenesis and tumor therapy

International Journal of Cancer

Volumn 106, Issue 3, 2003, Pages 458-459

  Linden, Tobias ^a   Wenger, Roland H ^b  

^a University of Labeck   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; DEFEROXAMINE; HYPOXIA INDUCIBLE FACTOR 1; IRON CHELATING AGENT; MATRIGEL; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RIBONUCLEOTIDE REDUCTASE; VASCULOTROPIN;

ANGIOGENESIS; CANCER THERAPY; CLINICAL RESEARCH; CONCENTRATION RESPONSE; DRUG METABOLISM; FIRST PASS EFFECT; HUMAN; IRON CHELATION; KAPOSI SARCOMA; LETTER; LIPOPHILICITY; PRIORITY JOURNAL; TUMOR VASCULARIZATION; WOUND HEALING;

ANTINEOPLASTIC AGENTS; CHELATION THERAPY; DEFEROXAMINE; ENDOTHELIUM, VASCULAR; HUMANS; IRON; IRON CHELATING AGENTS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0037828532     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11223     Document Type: Letter

References (11)

1. Clement PMJ, Hanauske-Abel HM, Wolff EC, Kleinman HK, Park MH. The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro. Int J Cancer 2002;100:491-8.
2. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000;43:S57-69.
3. Wanner RM, Spielmann P, Stroka DM, Camenisch G, Camenisch I, Scheid A, Houck DR, Bauer C, Gassmann M, Wenger RH. Epolones induce erythropoietin expression via hypoxia-inducible factor-1α activation. Blood 2000;96:1558-65.
4. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 1996;271:20291-9.
5. Farinelli SE, Greene LA. Cell cycle blockers mimosine, ciclopirox. and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J Neurosci 1996;16:1150-62.
6. 2-regulated gene expression. FASEB J 2002;16:1151-62.
7. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
8. Linden T, Katschinski DM, Eckhardt K, Scheid A, Pagel H, Wenger RH. The anti-mycotic ciclopirox olamine induces HIF-1α stability, VEGF expression and angiogenesis. FASEB J 2003;17: 761-3.
9. Chong TW, Horwitz LD, Moore JW, Sowter HM, Harris AL. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. Cancer Res 2002;62:6924-7.
10. Simonart T, Degraef C, Andrei G, Mosselmans R, Hermans P, Van Vooren JP, Noel JC, Boelaert JR, Snoeck R, Heenen M. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J Invest Dermatol 2000; 115:893-900.
11. Simonart T, Boelaert JR, Andrei G, van den Oord JJ, Degraef C, Hermans P, Noel JC, Van Vooren JP, Heenen M, De Clercq E, Snoeck R. Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model. Int J Cancer 2002;100:140-3.